🇺🇸 FDA
Pipeline program

MarzAA (marzeptacog alfa [activated])

MAA-102

Phase 1 mab completed

Quick answer

MarzAA (marzeptacog alfa [activated]) for Hemophilia A is a Phase 1 program (mab) at CATALYST PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
CATALYST PHARMACEUTICALS, INC.
Indication
Hemophilia A
Phase
Phase 1
Modality
mab
Status
completed

Clinical trials